Earnings calls

Jagsonpal Pharma concall ledger

Every earnings call for JAGSNPHARM — management tone, guidance, KPIs and promise tracking, quarter by quarter.

JAGSNPHARM · 3 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 28 Apr 2026Call held 28 Apr 2026

JAGSNPHARM Q4 FY26 Earnings Call Transcript & Analysis

Revenue₹64 cr+10% YoYEBITDA₹11 cr+9% YoYEBITDA Margin16%PAT₹9 cr+31% YoYPAT Margin14%

Revenue (Q4 FY26) ₹64 cr (+10% YoY); EBITDA (Q4 FY26) ₹11 cr (+9% YoY); EBITDA Margin (Q4 FY26) 16%. Q4 FY26 Revenue grew 10% YoY to INR64 crores, driven by sharpened execution focus.

Read full transcript & analysis

Q2 FY26Published 22 Jan 2026Call held 22 Jan 2026

JAGSNPHARM Q2 FY26 Earnings Call Transcript & Analysis

Revenue₹73 crEBITDA₹16.7 crEBITDA Margin22.7%PAT₹12.5 cr+10% YoYPAT Margin17.1%

Revenue (Q3) ₹73 cr; EBITDA (Q3) ₹17 cr; EBITDA Margin (Q3) 22.7%. Nine-month revenue grew 6% YoY to INR 223 crores.

Read full transcript & analysis

Q4 FY25Published 31 Jul 2025Call held 31 Jul 2025

JAGSNPHARM Q4 FY25 Earnings Call Transcript & Analysis

Revenue₹75.5 cr+23% YoYOperating EBITDA₹15.7 cr+24% YoYOperating EBITDA Margin20.8%PAT₹10.8 cr+100% YoY

Revenue ₹76 cr (+23% YoY); Operating EBITDA (pre-ESOP) ₹16 cr (+24% YoY); Operating EBITDA Margin 20.8%. Revenue grew 23% YoY to ₹75.5 crores.

Read full transcript & analysis